Aortic Valve Stenosis
Conditions
Keywords
aortic stenosis, aortic valve replacement, transcatheter aortic valve implantation, frailty, cardiac rehabilitation
Brief summary
This study will be evaluate the autonomic, endothelial and hemodynamic functions, inspiratory muscle strength, peripheral tissue oxygenation, peripheral and respiratory muscle architecture, and inflammatory profile of severe AS patients submitted undergoing to valve replacement (sAVR) or transcatheter aortic valve implantation (TAVI), and their influence on the pathophysiological mechanisms involved in cardiovascular rehabilitation.
Detailed description
Background: Aortic stenosis (AS) is a disease characterized by the inadequate valve opening, compromising the cardiac output. Surgical aortic valve replacement (sAVR) is the procedure indicates for valve repair in AS symptomatic cases whereas the transcatheter aortic valve implantation (TAVI) is the procedure indicates for sAVR contraindicated cases. Objective: To evaluate the effect of the cardiac rehabilitation program (pre-procedure, early post-procedure, and late post-procedure) in autonomic, endothelial and hemodynamic functions, inspiratory muscle strength, peripheral tissue oxygenation, peripheral and respiratory muscle architecture, and inflammatory profile of severe AS patients submitted to a valve repair procedure (sAVR or TAVI). Methods: The present study will be a randomized double-blind clinical trial in patients indicated to valve repair procedure. This research will be divided into four phases: phase 1 (pre-procedure); phase 2 (early post-procedure); phase 3 (late post-procedure) and phase 4 (follow-up). Phase 1: participants will be randomized in PR-I (pre-intervention) or PR-C (control). Pre-procedure rehabilitation program will consist of daily neuromuscular electrical stimulation (NMES) in knee extensor muscles and inspiratory muscle training (IMT) sessions. PR-C group will receive daily visits, but with a NMES + IMT protocols using a minimal load. Phase 2: a new random will be done between ER-II or ER-CI (intervention) and ER-IC or ER-CC (control). Intervention groups will undertake an early post-procedure rehabilitation (NMES in knee extensor muscle plus IMT for six weeks). Control groups will receive the same protocol using a minimal load without load progression. Phase 3: all patients will be referred to the conventional cardiac rehabilitation program (aerobic and resistance training) for 8-weeks. Phase 4: follow-up (no interventions), will be done after 3, 6, 9 and 12 months. Assessment protocol will be composed by cardiopulmonary exercise test, autonomic (heart rate variability), endothelial (flow-mediated vasodilation), hemodynamic function (cardiothoracic impedance) functional capacity (six-minute walk test), maximum inspiratory pressure, peripheral and respiratory muscle architecture (ultrasonography), and tissue oxygenation (near-infrared spectroscopy), and inflammatory profile (OxLDL, TGF-β, TNF-α, IL-1b, IL-10 and ICAM-1) Appropriate statistic tests will be used to compare the time-rehabilitation (experimental vs sham) and group-interaction (sAVR vs TAVI). If samples are abandoned or lost, basal data will be double entered to characterize the intention-to-treat analysis.
Interventions
BEHAVIORALcardiovascular rehabilitation program
Phase I: 2-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at hospital). Phase II: 6-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at home). Phase III: 8-weeks of supervised, structured, combined aerobic and resistance training.
Sponsors
Federal University of Health Science of Porto Alegre
Irmandade Santa Casa de Misericórdia de Porto Alegre
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Intervention model description
This study will be divided into four phases: phase 1 (pre-procedure rehabilitation); phase 2 (early post-procedure rehabilitation); phase 3 (late post-procedure rehabilitation), and phase 4 (follow-up).
Eligibility
Sex/Gender
ALL
Age
40 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
patients NYHA class II-IV who has not participated in a CRP three months before recruitment; older than 40 years; of both genders; with degenerative AS and indication for valve repair. The patients will not know which protocol to undergo.
Exclusion criteria
patients with low cognitive level to perform the assessment or intervention procedures; that exhibit unstable angina or any contraindications for the treatment or measurements; as well musculoskeletal, cerebrovascular, or psychiatric disease that prevents their participation in the research.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cardiorespiratory function | Changes from 8 and 16 weeks | Peak oxygen consumption (VO2PEAK), among other physiologic markers. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Endothelial function | Changes from 2, 8 and 16 weeks | will be investigated by endothelium-dependent flow-mediated vasodilation (FMD) technique following the International Brachial Artery Reactivity Task Force. |
| Hemodynamic function | Changes from 2, 8 and 16 weeks | will be evaluated the cardiac output using a cardiothoracic impedance device (noninvasive approach). |
| Inflammatory profile | Changes from 2, 8 and 16 weeks | Plasma levels will be determined by enzyme-linked immunosorbent assay using commercial systems. |
| Inspiratory muscle strength | Changes from 2, 8 and 16 weeks | Will be assessed as maximum inspiratory pressure (MIP) using a digital device following recommendations of the American Thoracic Society and European Respiratory Society. |
| Autonomic function | Change from 2, 8 and 16 weeks | will be evaluated by heart rate variability using a wrist heart rate monitor following the recommendations of ESC/NASPE Task Force. |
| Muscle architecture (respiratory muscles) | Changes from 8 and 16 weeks | Will be evaluated the diaphragm thickness (cross-sectional area) of quadriceps using a ultrasonography system. |
| Tissue oxygenation | Changes from 2, 8 and 16 weeks | near-infrared spectroscopy (NIRS) will be used to verify muscle oxygenation (quadriceps and respiratory muscles). |
| Functional capacity | Changes from 8 and 16 weeks | The patients under favorable clinical conditions will be functionally evaluated by the Six-Minute Walk Test (6MWT) according to current guidelines. |
| Mortality | Change from 3, 6 and 12 months post protocol | to evaluate the survival rate of the patients |
| Muscle architecture (peripheral muscles) | Changes from 8 and 16 weeks | Will be evaluated the muscle thickness (cross-sectional area) of quadriceps using a ultrasonography system. |
Countries
Brazil
Contacts
Primary ContactMarlus Karsten, PhD
Outcome results
None listed